[go: up one dir, main page]

EP1401424B1 - Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques - Google Patents

Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques Download PDF

Info

Publication number
EP1401424B1
EP1401424B1 EP02707927A EP02707927A EP1401424B1 EP 1401424 B1 EP1401424 B1 EP 1401424B1 EP 02707927 A EP02707927 A EP 02707927A EP 02707927 A EP02707927 A EP 02707927A EP 1401424 B1 EP1401424 B1 EP 1401424B1
Authority
EP
European Patent Office
Prior art keywords
formula
group
phenyl
alkyl
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02707927A
Other languages
German (de)
English (en)
Other versions
EP1401424A1 (fr
Inventor
Carlos R. Plata-Salaman
Boyu Zhao
Roy E. Twyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1401424A1 publication Critical patent/EP1401424A1/fr
Application granted granted Critical
Publication of EP1401424B1 publication Critical patent/EP1401424B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • This invention is directed to use of a carbamate compound in the manufacture of a medicament for preventing or treating psychotic disorders. More particularly, this invention is directed to use of halogenated 2-phenyl-1,2-ethanediol monocarbamate or dicarbamate compounds.
  • Psychotic disorders are those that are predominantly characterized by psychosis.
  • Psychosis is an impairment of mental functioning to the extent that it interferes grossly with an individual's ability to meet the ordinary demands of life.
  • psychotic means grossly impaired, in terms of reality testing. Such testing would define gross impairment as existing when individuals incorrectly evaluate the accuracy of their perceptions and thoughts and make incorrect inferences about external reality, even in the face of contrary evidence.
  • psychotic is also appropriate when behavior is so disorganized that it is reasonable to infer that results of reality testing would indicate an individual as grossly disturbed, for instance, by the existence of markedly incoherent speech without apparent awareness by the person that the speech is not understandable or by the agitated, inattentive and disoriented behavior observed in the phencyclidine psychotic disorder (Diagnostic and Statistical Manual of Mental Disorders, Ed. 4 th , American Psychiatric Association, Washington, DC 1994; Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Seventh Edition, Volume I, Lippincott Williams & Wilkins: Philadelphia, pp. 825, 2000).
  • Psychotic disorders include, and are not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder or psychotic disorder not otherwise specified (Diagnostic and Statistical Manual of Mental Disorders, Ed. 4 th , American Psychiatric Association, Washington, DC 1994).
  • Schizophrenia is any of a group of psychotic disorders usually characterized by withdrawal from reality, illogical patterns of thinking, delusions and hallucinations and accompanied in varying degrees by other emotional, behavioral or intellectual disturbances (Schizophrenia, Decision Resources, Inc., December 2000).
  • a lifelong chronic mental illness, schizophrenia exhibits several features including positive and negative symptoms, cognitive deficits, onset in young adulthood and deterioration from the previous level of functioning.
  • Positive symptoms reflect a distortion or excess of normal functions (eg, disorganized speech, delusions, hallucinations).
  • Negative symptoms reflect a restricted range of normal behavior and emotions (eg, apathy, paucity of speech and incongruity or flattening of emotional responses).
  • Schizophrenia can be presented in various forms depending on the symptoms and signs.
  • the varieties of schizophrenia include paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, and undifferentiated schizophrenia as well as post-schizophrenic depression, residual schizophrenia, simple schizophrenia and unspecified schizophrenia.
  • schizophrenia is conceptualized as a complex biological disorder in which genes play a role (but not an exclusive one) and in which brain development is likely to be abnormal.
  • Multiple abnormalities have been implicated in the pathophysiology of schizophrenia, including serotoninergic dysfunctions and abnormal dopminergic transmission which result in the impairment of sensormotor gating (Aghajanian GK, Marek GJ, Serotonin model of schizophrenia: emerging role of glutamate mechanisms, Brain Res. Rev., 2000, 31 (2-3), 302-12; Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE, Serotonergic basis of antipsychotic drug effects in schizophrenia, Biol.
  • antipsychotic drugs such as clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone are potent 5-HT2a receptor antagonists (Meltzer HY, The role of serotonin in antipsychotic drug action, Neuropsychopharmacology, 1999, 21 (2 Suppl), 106S-115S; and, Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE, Serotonergic basis of antipsychotic drug effects in schizophrenia, Biol. Psychiatry, 1998 Dec 1, 44 (11), 1099-1117).
  • DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride) is an hallucinogen having high affinity and selectivity as an agonist at 5-HT2A/2C receptors (Dowd CS, Herrick-Davis K, Egan C, DuPre A, Smith C, Teitler M, Glennon RA, 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists, J. Med. Chem., 2000, 43 (16), 3074-84; Yan QS, Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission, Brain Res.
  • DOI 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane
  • DOI administration produces dose-related behavioral effects including head shakes.
  • antipsychotics such as risperidone, haloperidol, clozapine and olanzapine antagonize the behavioral effects of DOI.
  • the prepulse inhibition (PPI) animal model (wherein a reduced startle reflex occurs in dopamine-activated rodents when a startling stimulus is preceded 30 to 500 msec by a weak stimulus or prepulse) and is predictive of clinical antipsychotic potency in a subgroup of schizophrenia patients who have dopaminergic deficits (Vollenweider, Franz X. and Geyer, Mark A., A systems model of altered consciousness: integrating natural and drug-induced psychoses, Brain Research Bulletin, 2001, 56, 5, 495-507; Braff, D.L., Geyer, M.A.
  • schizophrenia is a disease of multifaceted origin
  • the different animal models used to predict the efficacy of an antipsychotic drug may suggest that the drug has a specific mechanism of action (for example, affecting serotoninergic or dopaminergic transmission) in different patient populations.
  • Substituted phenyl alkyl carbamate compounds have been described in US Patent No. 3,265,728 to Bossinger, et al as useful in treating the central nervous system, having tranquilization, sedation and muscle relaxation properties of the formula: wherein R 1 is either carbamate or alkyl carbamate containing from 1 to 3 carbon atoms in the alkyl group; R 2 is either hydrogen, hydroxy, alkyl or hydroxy alkyl containing from 1 to 2 carbons; R 3 is either hydrogen or alkyl containing from 1 to 2 carbons; and X can be halogen, methyl, methoxy, phenyl, nitro or amino.
  • halogen substituted 2-phenyl-1,2-ethanediol monocarbamates and dicarbamates have also been described in US Patent No. 6,103,759 to Choi, et al, as effective for treating and preventing central nervous system disorders including convulsions, epilepsy, stroke and muscle spasm; and as useful in the treatment of central nervous system diseases, particularly as anticonvulsants, antiepileptics, neuroprotective agents and centrally acting muscle relaxants, of the formulae: wherein one enantiomer predominates and wherein the phenyl ring is substituted at X with one to five halogen atoms selected from fluorine, chlorine, bromine or iodine atoms and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each selected from hydrogen and straight or branched alkyl groups with one to four carbons optionally substituted with a phenyl group with substituents selected from the group consisting of hydrogen,
  • Halogen substituted 2-phenyl-1,2-ethanediol carbamate compounds of Formula (I) or Formula (II) have not been previously described as useful for preventing or treating psychotic disorders. Recent preclinical studies have revealed previously unrecognized pharmacological properties which suggest that a compound of Formula (I) or Formula (II) is useful in preventing or treating psychotic disorders. Therefore, an object of the present invention is the use of a compound of Formula (I) or Formula (II)-for the manufacture of a medicament for preventing or treating psychotic disorders.
  • the present invention is the use of a compound I or II below for the manufacture of a medicament for preventing or treating psychotic disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; wherein C 1 -C 4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro and cyano).
  • Embodiments of the invention use a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of Formula (I) and Formula (II).
  • Embodiments of the invention include the use of a compound selected from the group consisting of Formula (I) and Formula (II) for the preparation of a medicament for preventing or treating psychotic disorders in a subject in need thereof.
  • Embodiments of the method include the use of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates.
  • an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates preferably, one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 90% or greater. More preferably, one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 98% or greater.
  • the present invention is directed to the use in the manufacture of a medicament of a compound selected from the group consisting of Formula (I) and Formula (II): wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; wherein C 1 -C 4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro and cyano). for preventing or treating psychotic disorders.
  • the present method includes the use of a compound selected from the group consisting of Formula (I) and Formula (II) wherein X is chlorine; preferably, X is substituted at the ortho position of the phenyl ring.
  • the present method also includes the use of a compound selected from the group consisting of Formula (I) and Formula (II) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferably selected from hydrogen.
  • An embodiment of the present method includes the use of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates wherein X is chlorine; preferably, X is substituted at the ortho position of the phenyl ring.
  • the present method also includes the use of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferably selected from hydrogen.
  • an enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates preferably, an enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 90% or greater. More preferably, an enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 98% or greater.
  • An embodiment of the present method includes the use of an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; wherein C 1 -C 4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro and cyano).
  • the present method includes the use of an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates wherein X is chlorine; preferably, X is substituted at the ortho position of the phenyl ring.
  • the present method also includes the use of an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferably selected from hydrogen.
  • an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates preferably, an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 90% or greater. More preferably, an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 98% or greater.
  • An embodiment of the present method includes a method for preventing or treating psychotic disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates:
  • an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates preferably, an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 90% or greater. More preferably, an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 98% or greater.
  • a carbamate enantiomer selected from the group consisting of Formula (I), Formula (II), Formula (Ia), Formula (IIa), Formula (Ib) and Formula (IIb) contains an asymmetric chiral carbon atom at the benzylic position, which is the aliphatic carbon adjacent to the phenyl ring (represented by the asterisk in the structural formulae).
  • Psychotic disorders include, and are not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder or psychotic disorder not otherwise specified. More particularly, schizophrenia includes, and is not limited to, paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, post-schizophrenic depression, residual schizophrenia, simple schizophrenia or unspecified schizophrenia.
  • An example of the present invention comprises a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II) in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of Formula (I) and Formula (II).
  • the method of the present invention also includes the use of a compound selected from the group consisting of Formula (I) and Formula (II) for the preparation of a medicament for preventing or treating psychotic disorders.
  • Another example of the present invention comprises a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II) or a pharmaceutical composition thereof in combination with one or more agents useful in preventing or treating psychotic disorders.
  • a compound selected from the group consisting of Formula (I) and Formula (II) or pharmaceutical composition thereof may be administered by any conventional route of administration including, but not limited to oral, pulmonary, intraperitoneal (ip), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, buccal, nasal, sublingual, ocular, rectal and vaginal.
  • administration directly to the nervous system may include, and are not limited to, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal or peri-spinal routes of administration by delivery via intracranial or intravertebral needles or catheters with or without pump devices. It will be readily apparent to those skilled in the art that any dose or frequency of administration that provides the therapeutic effect described herein is suitable for use in the present invention.
  • the therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II) or pharmaceutical composition thereof may be from 0.01 mg/Kg/dose to 100 mg/Kg/dose.
  • the therapeutically effective amount may be from 0.01 mg/Kg/dose to 25 mg/Kg/dose. More preferably, the therapeutically effective amount may be from 0.01 mg/Kg/dose to 10 mg/Kg/dose. Most preferably, the therapeutically effective amount may be from 0.01 mg/Kg/dose to 5 mg/Kg/dose.
  • the therapeutically effective amount of the active ingredient contained per dosage unit e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like
  • the therapeutically effective amount of the active ingredient contained per dosage unit may be from 1 mg/day to 7000 mg/day for a subject, for example, having an average weight of 70 Kg.
  • the dosages may be varied depending upon the requirement of the subjects (including factors associated with the particular subject being treated, including subject age, weight and diet, strength of the preparation, the advancement of the disease condition and the mode and time of administration) and the use of a particular compound of Formula (I) or Formula (II) or pharmaceutical composition thereof.
  • Optimal dosages to be administered may be readily determined by those skilled in the art and will result in the need to adjust the dose to an appropriate therapeutic level.
  • the use of either daily administration or post-periodic dosing may be employed.
  • a compound of Formula (I) or Formula (II) or pharmaceutical composition thereof for treating psychotic disorders is administered orally or parenterally.
  • a compound of Formula (I) or Formula (II) or pharmaceutical composition thereof described herein may be administered separately, at different times during the course of therapy or concurrently in divided combination or single combination forms.
  • a compound selected from the group consisting of Formula (I) and Formula (II) or pharmaceutical compositions thereof may be administered in a single daily dose or the total daily dosage may be administered via continuous delivery or in divided doses of two, three or four times daily.
  • the instant invention is therefore to be understood as embracing all such methods and regimes of continuous, simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • a compound of Formula (I) or Formula (II) as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral).
  • a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral).
  • Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
  • a pharmaceutical composition is in a unit dosage form such as a tablet, pill, capsule, caplet, gelcap, lozenge, granule, powder, sterile parenteral solution or suspension, metered aerosol or liquid spray, drop, ampoule, autoinjector device or suppository for administration by oral, intranasal, sublingual, intraocular, transdermal, parenteral, rectal, vaginal, inhalation or insufflation means.
  • the composition may be presented in a form suitable for once-weekly or once-monthly administration or may be adapted to provide a preparation for intramuscular injection.
  • suitable carriers and additives include but are not limited to diluents, granulating agents, lubricants, binders, glidants, disintegrating agents and the like. If desired, tablets may be sugar coated, gelatin coated, film coated or enteric coated by standard techniques.
  • the principal active ingredient is mixed with a pharmaceutical carrier (e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and glidants).
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and glidants.
  • Sweeteners and flavorants may be added to chewable solid dosage forms to improve the palatability of the oral dosage form.
  • colorants and coatings may be added or applied to the solid dosage form for ease of identification of the drug or for aesthetic purposes.
  • These carriers are formulated with the pharmaceutical active to provide an accurate, appropriate dose of the pharmaceutical active with a therapeutic release profile.
  • any of the usual pharmaceutical media or excipients may be employed.
  • suitable carriers and additives include but are not limited to pharmaceutically acceptable wetting agents, dispersants, flocculation agents, thickeners, pH control agents (i.e. buffers), osmotic agents, coloring agents, flavors, fragrances, preservatives (i.e. to control microbial growth, etc.) and a liquid vehicle may be employed. Not all of the components listed above will be required for each liquid dosage form.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, but are not limited to aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • DOI DOI-derived neurodegenerative disease .
  • the administration of DOI to rodents has been used as a model for assessing potential efficacy of an atypical antipsychotic in treating psychosis and schizophrenia in certain patient populations with direct or indirect defects in the serotonin system.
  • mice Male NIH Swiss mice weighing 18-21 grams at the time of purchase were obtained from Harlan Sprague Dawley, Inc. (Prattville, AL). They were individually housed in wire-mesh cages at an ambient temperature of 21 to 23 °C with an automated 12/12 hour light/dark cycle. All rats had free access to 5001 Rodent Chow (Purina Mills, Brentwood, MO) and water except during experimental sessions. The principles of laboratory animal care (NIH publication No. 85-23, revised 1985) were followed.
  • DOI (purchased from Sigma, St. Louis, MO) was dissolved in saline, neutralized to pH ⁇ 7.4 and injected ip in a volume of 10 ml/kg body weight. Injection solution was freshly prepared 30-45 minutes before each experiment. Methylcellulose (0.5%, Sigma) was used as oral dosing vehicle. All experiments were performed between 10 am and 4 pm during the day. The mice were fasted the evening before the experiment.
  • mice were placed in isolated observation cylinders made of a clear polycarbonate (27 cm in diameter and 55 cm deep). The number of randomized headshakes (or twitches) was recorded by an experienced observer using a hand held mechanical counter. Headshake responses were counted in consecutive 10-min periods.
  • the average of the headshakes in the vehicle group was 7.95 ⁇ 0.2, consistently obtained with 5 mg/kg of DOI (ip) in 382 mice.
  • An enantiomer of Formula (Ib) suppressed the frequency of DOI-induced headshakes dose-dependently with a maximal suppression of 76% at the 100 mg/kg dose. Similar effects, but less potent, were observed in mice treated with an enantiomer of Formula (IIb), having a maximal suppression of DOI-induced headshakes of 43% at 100 mg/kg.
  • Table 1 summarizes the experimental data (n is the number of animals per group): Table 1 % Inhibition Dose mg/Kg Formula (Ib) Formula (IIb) % Inh. n p value % Inh. n p value 0.01 11 6 0.20 1 6 0.50 0.1 20 6 0.08 11 6 0.25 1 41 6 ⁇ 0.01 4 6 0.48 10 63 10 ⁇ 0.001 41 6 ⁇ 0.05 30 58 5 ⁇ 0.01 36 6 ⁇ 0.05 100 76 5 ⁇ 0.001 43 6 ⁇ 0.05
  • PCP Pre-Pulse Inhibition
  • Sprague-Dawley-derived male rats were housed in groups of two or three and maintained in a temperature-controlled environment on a 12h:12h light cycle. Except during behavioral testing, animals were given free access to food and water. Animals were handled daily for several days to desensitize them to handling stress before behavioral analysis.
  • the rats were pretreated with an enantiomer of Formula (Ib) at 5, 15 and 45 mg/kg (p.o.) 110 minutes prior to treatment with PCP (1.5 mg/kg, s.c.) in saline in a volume of 1 ml/kg. Rats were placed 10 minutes later into individual startle chambers for testing. Clozapine (7.5mg/kg) was used as a positive control.
  • Testing was done with a 70 dB[A] background noise, followed by a series of startle trials, consisting of several conditions: 1) a 118 dB[A] noise burst over a 40 msec time period, or 2) a 118 dB[A] noise burst over a 40 msec time period preceded by prepulses (118 dB[A] noise bursts over a 20 msec time period) at 100 msec intervals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

  1. Utilisation d'un composé choisi dans le groupe constitué par la formule (I) et la formule (II):
    Figure imgb0014
     dans lesquelles
    le phényle est substitué au niveau de X par un à cinq atomes d'halogènes choisis dans le groupe constitué par le fluor, le chlore, le brome et l'iode; et,
    R1, R2, R3, R4, R5 et R6 sont choisis indépendamment dans le groupe constitué par l'hydrogène et un alkyle en C1 à C4; où l'alkyle en C1 à C4 est le cas échéant substitué par un phényle (le phényle étant le cas échéant substitué par des substituants choisis indépendamment dans le groupe constitué par un halogène, un alkyle en C1 à C4, un alcoxy en C1 à C4, un amino, un nitro et un cyano);
    dans un procédé de fabrication d'un médicament destiné à la prévention ou au traitement de troubles psychotiques.
  2. Utilisation selon la revendication 1, dans laquelle X est le chlore.
  3. Utilisation selon la revendication 1, dans laquelle X est substitué dans la position ortho du noyau cyclique phényle.
  4. Utilisation selon la revendication 1, dans laquelle R1, R2, R3, R4, R5 et R6 sont choisis parmi l'hydrogène.
  5. Utilisation d'un énantiomère choisi dans le groupe constitué par la formule (I) et la formule (II) ou d'un mélange d'énantiomères dans lequel un énantiomère choisi dans le groupe constitué par la formule (I) et la formule (II) prédomine:
    Figure imgb0015
     dans lesquelles
    le phényle est substitué au niveau de X par un à cinq atomes d'halogènes choisis dans le groupe constitué par le fluor, le chlore, le brome et l'iode; et,
    R1, R2, R3, R4, R5 et R6 sont choisis indépendamment dans le groupe constitué par l'hydrogène et un alkyle en C1 à C4; où l'alkyle en C1 à C4 est le cas échéant substitué par un phényle (le phényle étant le cas échéant substitué par des substituants choisis indépendamment dans le groupe constitué par un halogène, un alkyle en C1 à C4, un alcoxy en C1 à C4, un amino, un nitro et un cyano);
    dans un procédé de fabrication d'un médicament destiné à la prévention ou au traitement de troubles psychotiques.
  6. Utilisation selon la revendication 5, dans laquelle X est le chlore.
  7. Utilisation selon la revendication 5, dans laquelle X est substitué dans la position ortho du noyau cyclique phényle.
  8. Utilisation selon la revendication 5, dans laquelle R1, R2, R3, R4, R5 et R6 sont choisis parmi l'hydrogène.
  9. Utilisation selon la revendication 5, dans laquelle l'énantiomère choisi dans le groupe constitué par la formule (I) et la formule (II) est un énantiomère choisi dans le groupe constitué par la formule (Ib) et la formule (IIb):
    Figure imgb0016
  10. Utilisation selon la revendication 1 ou la revendication 5, dans laquelle les troubles psychotiques sont choisis parmi la schizophrénie, un trouble schizophréni-forme, un trouble schizoaffectif, un trouble hallucinatoire, un trouble psychotique bref, un trouble psychotique partagé, un trouble psychotique provoqué par une condition médicale générale, un trouble psychotique induit par une substance ou un trouble psychotique non spécifié par ailleurs.
EP02707927A 2001-02-27 2002-02-21 Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques Expired - Lifetime EP1401424B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27188901P 2001-02-27 2001-02-27
US271889P 2001-02-27
PCT/US2002/006119 WO2002067927A1 (fr) 2001-02-27 2002-02-21 Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques
US10/081,761 US6541513B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders
US81761 2002-02-21

Publications (2)

Publication Number Publication Date
EP1401424A1 EP1401424A1 (fr) 2004-03-31
EP1401424B1 true EP1401424B1 (fr) 2006-11-29

Family

ID=26765939

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707927A Expired - Lifetime EP1401424B1 (fr) 2001-02-27 2002-02-21 Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques

Country Status (25)

Country Link
US (1) US6541513B2 (fr)
EP (1) EP1401424B1 (fr)
JP (1) JP4276841B2 (fr)
KR (1) KR100886578B1 (fr)
CN (1) CN1262271C (fr)
AR (1) AR032876A1 (fr)
AT (1) ATE346597T1 (fr)
AU (1) AU2002242296B2 (fr)
BR (1) BR0207829A (fr)
CA (1) CA2439480C (fr)
CZ (1) CZ302412B6 (fr)
DE (1) DE60216457T2 (fr)
DK (1) DK1401424T3 (fr)
ES (1) ES2275844T3 (fr)
HU (1) HUP0303342A3 (fr)
IL (2) IL157588A0 (fr)
MX (1) MXPA03007722A (fr)
NO (1) NO20033801L (fr)
NZ (1) NZ527991A (fr)
PL (1) PL365021A1 (fr)
PT (1) PT1401424E (fr)
RS (1) RS51056B (fr)
RU (1) RU2302240C2 (fr)
TW (1) TWI251486B (fr)
WO (1) WO2002067927A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305082B1 (fr) * 2000-07-21 2004-05-26 Ortho-McNeil Pharmaceutical, Inc. Composes de carbamate destines a la prevention ou au traitement de douleurs neuropathiques et de douleurs associees a la cephalee vasculaire de horton et a la migraine
RU2292881C2 (ru) 2001-02-27 2007-02-10 Орто-Макнейл Фармасьютикал, Инк. Соединения карбамата для применения при профилактике или лечении тревожных расстройств
MXPA03007718A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para usarse en la prevencion o tratamiento de trastornos neurodegenerativos.
US20030083372A1 (en) 2001-07-16 2003-05-01 Codd Ellen C. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
WO2005107719A2 (fr) * 2004-05-06 2005-11-17 Sandoz Ag Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
KR101199499B1 (ko) * 2005-07-26 2012-11-09 얀센 파마슈티카 엔.브이. 물질 관련 장애를 치료하는 방법
EP2081648A2 (fr) * 2006-10-30 2009-07-29 Janssen Pharmaceutica, N.V. Procédés de traitement de la dépression
EA200970435A1 (ru) * 2006-10-31 2009-10-30 Янссен Фармацевтика, Н. В. Лечение общих расстройств развития
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
US9566261B2 (en) 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
CZ20032297A3 (cs) 2004-06-16
ATE346597T1 (de) 2006-12-15
NZ527991A (en) 2005-04-29
CN1505507A (zh) 2004-06-16
KR20030076713A (ko) 2003-09-26
US6541513B2 (en) 2003-04-01
PL365021A1 (en) 2004-12-27
CA2439480C (fr) 2011-04-26
AR032876A1 (es) 2003-11-26
IL157588A0 (en) 2004-03-28
WO2002067927A1 (fr) 2002-09-06
IL157588A (en) 2009-12-24
TWI251486B (en) 2006-03-21
RU2003128983A (ru) 2005-03-10
CN1262271C (zh) 2006-07-05
KR100886578B1 (ko) 2009-03-05
JP2004523556A (ja) 2004-08-05
US20020165272A1 (en) 2002-11-07
BR0207829A (pt) 2004-06-22
PT1401424E (pt) 2007-02-28
JP4276841B2 (ja) 2009-06-10
HUP0303342A3 (en) 2012-07-30
DE60216457D1 (de) 2007-01-11
EP1401424A1 (fr) 2004-03-31
CZ302412B6 (cs) 2011-05-04
NO20033801L (no) 2003-10-22
DE60216457T2 (de) 2007-09-20
MXPA03007722A (es) 2004-11-12
ES2275844T3 (es) 2007-06-16
RS51056B (sr) 2010-10-31
NO20033801D0 (no) 2003-08-26
RU2302240C2 (ru) 2007-07-10
CA2439480A1 (fr) 2002-09-06
AU2002242296B2 (en) 2006-06-29
RS67503A (en) 2006-12-15
DK1401424T3 (da) 2007-02-26
HUP0303342A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
RU2338537C2 (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
KR101783632B1 (ko) 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
ES2433080T3 (es) Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
RU2653408C2 (ru) Способы лечения биполярного расстройства
EP1401424B1 (fr) Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques
AU2002242296A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
JP2004527492A (ja) 運動障害の予防もしくは治療における使用のためのカルバメート化合物
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
AU780817B2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AU2005335241B2 (en) Methods for treating substance-related disorders
ES2963362T3 (es) Métodos de uso de derivados de amidas cíclicas para tratar la esquizofrenia y sus síntomas
EP4489741A1 (fr) Compositions comprenant du meai et des n-acylethanolamines et leurs utilisations
US20230201150A1 (en) The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia
EP3096790B1 (fr) Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
ZA200307469B (en) Carbamate compounds for use in preventing or treating psychotic disorders.
EP1545546B1 (fr) Traitement de la dyskinésie avec des 2,3-benzodiazépines
US20020137767A1 (en) Methods for treating addictive disorders
WO2018029685A1 (fr) Compositions et méthodes de traitement d'une infection virale

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60216457

Country of ref document: DE

Date of ref document: 20070111

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070228

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070117

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070400388

Country of ref document: GR

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2275844

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061129

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20110210

Year of fee payment: 10

Ref country code: DK

Payment date: 20110210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20110330

Year of fee payment: 10

Ref country code: PT

Payment date: 20110207

Year of fee payment: 10

Ref country code: FR

Payment date: 20110218

Year of fee payment: 10

Ref country code: NL

Payment date: 20110216

Year of fee payment: 10

Ref country code: IT

Payment date: 20110216

Year of fee payment: 10

Ref country code: TR

Payment date: 20110128

Year of fee payment: 10

Ref country code: CH

Payment date: 20110214

Year of fee payment: 10

Ref country code: AT

Payment date: 20110126

Year of fee payment: 10

Ref country code: SE

Payment date: 20110211

Year of fee payment: 10

Ref country code: DE

Payment date: 20110216

Year of fee payment: 10

Ref country code: FI

Payment date: 20110211

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20110113

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20110216

Year of fee payment: 10

Ref country code: ES

Payment date: 20110315

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20110722

Year of fee payment: 10

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120223 AND 20120229

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20120301 AND 20120307

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60216457

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT, DE

Effective date: 20120216

Ref country code: DE

Ref legal event code: R081

Ref document number: 60216457

Country of ref document: DE

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Free format text: FORMER OWNER: ORTHO-MCNEIL PHARMACEUTICAL, INC., RARITAN, US

Effective date: 20120216

Ref country code: DE

Ref legal event code: R081

Ref document number: 60216457

Country of ref document: DE

Owner name: SK BIOPHARMACEUTICALS CO., LTD., KR

Free format text: FORMER OWNER: ORTHO-MCNEIL PHARMACEUTICAL, INC., RARITAN, N.J., US

Effective date: 20120216

Ref country code: DE

Ref legal event code: R082

Ref document number: 60216457

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

Effective date: 20120216

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20120821

BERE Be: lapsed

Owner name: ORTHO-MCNEIL PHARMACEUTICAL, INC.

Effective date: 20120228

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120221

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20070400388

Country of ref document: GR

Effective date: 20120905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120222

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120905

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120821

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60216457

Country of ref document: DE

Effective date: 20120901

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 346597

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120221